Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia

© 2016 Informa UK Limited, trading as Taylor & Francis Group. Objectives: To study the clinical manifestations, outcomes, and survival of warm-type autoimmune hemolytic anemia (AIHA) patients. Methods: This study was a retrospective single-center study from 2002 to 2013. Clinical data of AIHA...

Full description

Saved in:
Bibliographic Details
Main Authors: Rattarittamrong E., Eiamprapai P., Tantiworawit A., Rattanathammethee T., Hantrakool S., Chai-Adisaksopha C., Norasetthada L.
Format: Journal
Published: 2017
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84978493510&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/41730
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-41730
record_format dspace
spelling th-cmuir.6653943832-417302017-09-28T04:23:05Z Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia Rattarittamrong E. Eiamprapai P. Tantiworawit A. Rattanathammethee T. Hantrakool S. Chai-Adisaksopha C. Norasetthada L. © 2016 Informa UK Limited, trading as Taylor & Francis Group. Objectives: To study the clinical manifestations, outcomes, and survival of warm-type autoimmune hemolytic anemia (AIHA) patients. Methods: This study was a retrospective single-center study from 2002 to 2013. Clinical data of AIHA patients were reviewed and analyzed. Results: One hundred and one patients were included, of whom 77% were female with a median age of 43 years. Primary AIHA was found in 61% of the patients. The secondary causes were systemic lupus erythematosus (SLE) (64%), solid malignancies (13%), lymphomas (10%), drugs (8%), and infections (5%). Most patients (96%) responded to steroids, which were not different between primary and secondary AIHA. Second-line treatments were required in 33 patients (33%). The indications were steroid dependence (58%), relapse (30%), and others (12%). The most common second-line treatment was cyclophosphamide (52%). The response rate for second-line treatments was 93%. Relapse occurred in 50 patients (50%) in which 58% occurred more than 3 years after diagnosis. The SLE patients relapsed and received second-line therapy more than the non-SLE group (P < 0.001). At the median 53-month follow-up, the overall survival (OS) was 84%. The independent risk factors for OS were age more than 50 years and malignancy. Sepsis was the most common cause of death. Discussion and conclusion: AIHA has a good prognosis and long-term survival especially in young patients without malignancy. Most patients have responded initially to steroids and have a high response rate to second-line therapy. Carefully adjusted and rapid taper of immunosuppressant is necessary to avoid sepsis complications. 2017-09-28T04:23:05Z 2017-09-28T04:23:05Z 2016-07-02 Journal 10245332 2-s2.0-84978493510 10.1080/10245332.2016.1138621 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84978493510&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/41730
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
description © 2016 Informa UK Limited, trading as Taylor & Francis Group. Objectives: To study the clinical manifestations, outcomes, and survival of warm-type autoimmune hemolytic anemia (AIHA) patients. Methods: This study was a retrospective single-center study from 2002 to 2013. Clinical data of AIHA patients were reviewed and analyzed. Results: One hundred and one patients were included, of whom 77% were female with a median age of 43 years. Primary AIHA was found in 61% of the patients. The secondary causes were systemic lupus erythematosus (SLE) (64%), solid malignancies (13%), lymphomas (10%), drugs (8%), and infections (5%). Most patients (96%) responded to steroids, which were not different between primary and secondary AIHA. Second-line treatments were required in 33 patients (33%). The indications were steroid dependence (58%), relapse (30%), and others (12%). The most common second-line treatment was cyclophosphamide (52%). The response rate for second-line treatments was 93%. Relapse occurred in 50 patients (50%) in which 58% occurred more than 3 years after diagnosis. The SLE patients relapsed and received second-line therapy more than the non-SLE group (P < 0.001). At the median 53-month follow-up, the overall survival (OS) was 84%. The independent risk factors for OS were age more than 50 years and malignancy. Sepsis was the most common cause of death. Discussion and conclusion: AIHA has a good prognosis and long-term survival especially in young patients without malignancy. Most patients have responded initially to steroids and have a high response rate to second-line therapy. Carefully adjusted and rapid taper of immunosuppressant is necessary to avoid sepsis complications.
format Journal
author Rattarittamrong E.
Eiamprapai P.
Tantiworawit A.
Rattanathammethee T.
Hantrakool S.
Chai-Adisaksopha C.
Norasetthada L.
spellingShingle Rattarittamrong E.
Eiamprapai P.
Tantiworawit A.
Rattanathammethee T.
Hantrakool S.
Chai-Adisaksopha C.
Norasetthada L.
Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia
author_facet Rattarittamrong E.
Eiamprapai P.
Tantiworawit A.
Rattanathammethee T.
Hantrakool S.
Chai-Adisaksopha C.
Norasetthada L.
author_sort Rattarittamrong E.
title Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia
title_short Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia
title_full Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia
title_fullStr Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia
title_full_unstemmed Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia
title_sort clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia
publishDate 2017
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84978493510&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/41730
_version_ 1681422056106754048